ReviewHematological oncology2025
First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.
Review in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06482684 (Early Treatment Intensification in Patients With High Risk Mantle Cell Lymphoma Using CAR-T-cell Treatment After an Abbreviated Induction Therapy With Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Treatment Intensification in Patients With High Risk Mantle Cell Lymphoma Using CAR-T-cell Treatment After an Abbreviated Induction Therapy With Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) as Compared to Standard of Care Induction and Maintenance (Arm B)
Who cites it
2 citing papers in PubMed.
- First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.Current oncology (Toronto, Ont.) · 2026Review
- T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions.European journal of haematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development and implementation of new targeted and immunotherapeutic approaches in the treatment landscape of mantle cell lymphoma have already improved therapeutic options especially for refractory or relapsed disease. Regarding first-line therapy, treatment strategies including novel agents are under investigation. In transplant-eligible patients, a combined ibrutinib-containing immunochemotherapy induction followed by ASCT was shown to be superior compared to the chemotherapy regimen +/- ASCT. Thus, we consider the addition of ibrutinib to first-line therapy in younger MCL patients a new standard of care. For the group of older MCL patients ineligible for high-dose therapy and ASCT, several targeted therapy approaches have been investigated in different studies in combination with immunochemotherapies or as single agents +/- other targeted therapies with promising results. This review summarizes the current standard of care for first-line treatment of mantle cell lymphoma, highlighting the implementation of targeted treatment strategies, especially BTKi, in initial treatment strategies. Trial Registration: ClinicalTrials.gov identifier: NCT06482684.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.